FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * Bolzon Bradley J PhD 2. Issuer Name and Ticker or Trading Symbol CRISPR Therapeutics AG [ CRSP ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)__X__ Director                    _____ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)         (First)         (Middle)
C/O CRISPR THERAPEUTICS, INC., 610 MAIN STREET
3. Date of Earliest Transaction (MM/DD/YYYY)
2/19/2021
(Street)
CAMBRIDGE, MA 02139
(City)       (State)       (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Shares  2/19/2021    S    78200 (1) D $147.7886 (2) 261634  I  See Footnote (3)
Common Shares  2/19/2021    S    23276 (1) D $149.2432 (4) 238358  I  See Footnote (3)
Common Shares  2/19/2021    S    38132 (1) D $150.1042 (5) 200226  I  See Footnote (3)
Common Shares  2/19/2021    S    27932 (1) D $150.9903 (6) 172294  I  See Footnote (3)
Common Shares  2/19/2021    S    3463 (1) D $151.8198 (7) 168831  I  See Footnote (3)
Common Shares  2/19/2021    J(8)    615607  D $0.00  720481  I  See Footnote (9)
Common Shares  2/19/2021    J(10)    158522  A $0.00  158522  I  See Footnote (11)
Common Shares  2/19/2021    J(12)    158522  D $0.00  0  I  See Footnote (11)
Common Shares  2/19/2021    J(13)    27716  A $0.00  27716  D   
Common Shares  2/19/2021    J(14)    3650  D $0.00  4272  I  See Footnote (15)
Common Shares  2/19/2021    J(16)    366084  D $0.00  826055  I  See Footnote (17)
Common Shares  2/19/2021    J(18)    79074  A $0.00  79074  I  See Footnote (19)
Common Shares  2/19/2021    J(20)    11011  D $0.00  23966  I  See Footnote (21)
Common Shares  2/19/2021    J(22)    2378  A $0.00  81452  I  See Footnote (19)
Common Shares  2/19/2021    J(23)    12189  D $0.00  26583  I  See Footnote (24)
Common Shares  2/19/2021    J(25)    2633  A $0.00  84085  I  See Footnote (19)
Common Shares  2/19/2021    J(26)    84085  D $0.00  0  I  See Footnote (19)
Common Shares  2/19/2021    J(27)    18973  A $0.00  46689  D   
Common Shares  2/19/2021    J(28)    27861  D $0.00  62869  I  See Footnote (29)
Common Shares  2/19/2021    J(30)    6018  A $0.00  6018  I  See Footnote (31)
Common Shares  2/19/2021    J(32)    6018  D $0.00  0  I  See Footnote (31)
Common Shares  2/19/2021    J(33)    847  A $0.00  47536  D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:
(1)  These securities are held of record by Versant Venture Management LLC ("VVM LLC"), a portion of which are held for the benefit of the Reporting Person, pursuant to an agreement between VVM LLC and the Reporting Person.
(2)  The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $147.60 to $148.56, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
(3)  These securities are held of record by VVM LLC. The Reporting Person is a managing member of VVM LLC and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any.
(4)  The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $148.61 to $149.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.
(5)  The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $149.61 to $150.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (5) to this Form 4.
(6)  The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $150.61 to $151.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (6) to this Form 4.
(7)  The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $151.61 to $151.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (7) to this Form 4.
(8)  Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital IV, L.P. ("VVC IV") to its partners.
(9)  These securities are held of record by VVC IV. Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and dispositive power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
(10)  Represents a change in the form of ownership of VV IV by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VVC IV.
(11)  Shares held of record by VV IV. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
(12)  Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV IV to its members.
(13)  Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VV IV.
(14)  Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Side Fund IV, L.P. ("VSF IV") to its partners.
(15)  These securities are held of record by VSF IV. VV IV is the sole general partner of VSF IV and may be deemed to have voting and dispositive power over the securities held by VSF IV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
(16)  Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital V, L.P. ("VVC V") to its partners.
(17)  These securities are held of record by VVC V. Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V and may be deemed to have voting and dispositive power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
(18)  Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VVC V.
(19)  Shares held of record by VV V. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
(20)  Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Affiliates Fund V, L.P. ("VAF V") to its partners.
(21)  These securities are held of record by VAF V. VV V is the sole general partner of VAF V and may be deemed to have voting and dispositive power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
(22)  Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VAF V.
(23)  Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Ophthalmic Affiliates Fund I, L.P. ("VOA") to its partners.
(24)  These securities are held of record by VOA. VV V is the sole general partner of VOA and may be deemed to have voting and dispositive power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
(25)  Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VOA.
(26)  Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV V to its members.
(27)  Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VV V.
(28)  Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital V (Canada) LP ("VVC CAN") to its partners.
(29)  These securities are held of record by VVC CAN. Versant Ventures V GP-GP (Canada), Inc. ("VV V CAN GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V CAN") and VV V CAN is the sole general partner of VVC CAN. Each of VV V CAN GP and VV V CAN may be deemed to have voting and dispositive power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a director of VV V CAN GP and may be deemed to indirectly beneficially own the securities through his interest in VV V CAN GP. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any.
(30)  Represents a change in the form of ownership of VV V CAN by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VVC CAN.
(31)  Shares held by VV V CAN. VV V CAN GP is the sole general partner of VV V CAN. VV V CAN GP may be deemed to have voting and dispositive power over the securities held by VV V CAN and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a director of VV V CAN GP and may be deemed to indirectly beneficially own the securities through his interest in VV V CAN GP. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any.
(32)  Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV V CAN to its partners.
(33)  Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VV V CAN.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Bolzon Bradley J PhD
C/O CRISPR THERAPEUTICS, INC.
610 MAIN STREET
CAMBRIDGE, MA 02139
X



Signatures
/s/ Robin L. Praeger, attorney-in-fact for Bradley Bolzon 2/23/2021
**Signature of Reporting Person Date